Vivus sues Actavis over Qsymia patent challenge; Sri Lanka eyes generics-first prescribing policy;

@FiercePharma: Roche neighbors sue, claiming contamination lowered home prices. More | Follow @FiercePharma

@EricPFierce: ICYMI: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. Story | Follow @EricPFierce

@CarlyHFierce: German court deals another EU patent blow to Lilly's blockbuster Alimta. Article | Follow @CarlyHFierce

> U.S.-based Vivus ($VVUS) sued Actavis ($ACT) for infringement after the generics maker challenged two patents on Vivus' obesity drug Qsymia, which combines two older drugs, phentermine and topiramate. Filing

> Sri Lanka's government is set to launch a new drug policy requiring doctors to prescribe generics if a copycat drug is available. Report

> The U.S. Supreme Court sent a University of Notre Dame contraception case back to a lower court to be reviewed in light of a related high court ruling in the Hobby Lobby case. Report

> Reig Jofre and Kern Pharma inked a deal with Maruishi Pharma to market an injectable anesthetic for hospital use in Japan. Report

> Novo Nordisk ($NVO) released data suggesting that its new obesity drug Saxenda could help fight weight-related health problems as patients lose weight. Report

Medical Device News

@FierceMedDev: ICYMI Friday: J&J ordered to hand over $5.6M in vaginal mesh trial. Report | Follow @FierceMedDev

@VarunSaxena2: Four clinical trial patients die in test of Sunshine Heart ventricle assist device. Story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's edition of FierceLifeSci here! | Follow @EmilyWFierce

> Patient advocates call for increased transparency as superbug tied to endoscopes continues. News

> FDA approves novel blood purifier that treats rare condition in hemodialysis patients. Story

> Icon launches new medical device research division. Article

Biotech News

@FierceBiotech: Baxter and its controversial partner CTI claim a win in PhIII blood cancer study. Report | Follow @FierceBiotech

@JohnCFierce: From the weekend file: UPDATED: Merck to shutter Cubist unit in May, axing most of the 128 R&D staffers. Report | Follow @JohnCFierce

@DamianFierce: Hey @FierceBiotech's podcast is now available on Stitcher. If you know what that means, here you go. | Follow @DamianFierce

> Biopharma's new normal: Constant makeovers leave R&D jobs at permanent risk. Story

> Baxter and its controversial partner CTI claim a win in PhIII blood cancer study. News

> AcelRx hammered (again) after FDA demands a new Zalviso study after all. Article

Biotech IT News

> NIH puts data stitching at top of precision medicine to-do list. More

> Broadly positive reactions roll in for FDA's drug shortages app. Report

> Ubisoft creates therapeutic video game to treat lazy eye. Item

> Intel-GE joint venture teams with Xavier U. to test health tech. Story

> AstraZeneca's rapid-fire IT dealmaking continues with Elixir hookup. Article

CRO News

> Altasciences partners up for early-stage R&D. Article

> Contractor Almac gets into the clinic with a candidate of its own. More

> Icon doubles down on med tech with latest offering. Story

> Patheon snags another CMO amid its global expansion. News

> WuXi eyes major growth in 2015 with plans to spend big. Article

Animal Health News

> Heska scores record 2014 sales on 'more focused' strategy. More

> EMA seeks input on new guidelines to combat antibiotics resistance. Item

> Researchers tap dogs for insights into stopping cancer metastasis. Article

> Future veterinarians go to Congress to discuss student loan debt. Story

> McDonald's ditches antibiotics-raised chicken as legislators launch bill to curb use. Report

And Finally... A new National Health Service heart-age calculator is stirring up some protest. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.